Virtu Financial’s TScan Therapeutics TCRX Stock Holding History

Virtu Financial’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,140	Closed	-$18K	–	2231
2026 Q1	$18K	Buy	+18,140	New	+$19.4K	﹤0.01%	1405
2025 Q4	–	Sell	-60,480	Closed	-$110K	–	2221
2025 Q3	$110K	Buy	60,480 +49,092	+431%	+$87K	0.01%	1031
2025 Q2	$17K	Buy	11,388 +365	+3%	+$527	﹤0.01%	1271
2025 Q1	$15K	Buy	+11,023	New	+$23.8K	﹤0.01%	1144
2024 Q1	–	Sell	-18,418	Closed	-$107K	–	2083
2023 Q4	$107K	Buy	+18,418	New	+$84.3K	0.01%	1017

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Virtu Financial's TCRX Position: Q2 2026 in Review

Virtu Financial sold out of TScan Therapeutics (TCRX) in Q2 2026, closing a stake of 18,140 shares — an estimated $18K sold.

Virtu Financial first reported a position in TCRX in Q4 2023 and held it in 5 quarters. The position peaked at $110K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Virtu Financial reported no remaining TScan Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 18,140 TScan Therapeutics shares in Q2 2026, an estimated $18K.
Virtu Financial first reported a position in TScan Therapeutics in Q4 2023 and held it in 5 quarters.
Virtu Financial's TScan Therapeutics position peaked at $110K in Q3 2025.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.